Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA4 | P22748 | 2/20 | 0.69 |
| ▸ | CA6 | P23280 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | TPMT | P51580 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | TTR | P02766 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL28816780 | 0.93 | CA12 (0.66) | CA12CA1CA2CA4CA6 | |
| SCHEMBL27456578 | 0.86 | CYP1A2 (0.68) | CA12CA1CA2CA4CA6 | |
| SCHEMBL21501292 | 0.85 | MEN1 (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8195142 | 0.85 | LMNA (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3856127 | 0.85 | CYP1A2 (0.50) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29524334 | 0.85 | TPMT (0.69) | CA12CA1CA2CA4CA6 | |
| SCHEMBL308170 | 0.85 | TPMT (0.69) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2253933 | 0.83 | MAPT (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2762379 | 0.83 | MAPK1 (0.58) | CA12CA1CA2CA4CA6 | |
| Hydrochloric Acid SCHEMBL306990 | 0.83 | CA12 (0.67) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | claimed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| CN-119751241-A | Preparation method of biphenyl-2-carboxylic acid compound at room temperature | 扬州大学 | 2025-04-04 | — | — | CN | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-5981768-A | SUITABLE FOR USE IN A WIDE VARIETY OF ASSAYS AND OTHER DETECTION APPLICATIONS | TROPIX, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5869699-A | STABLE DIOXETANE BEARING A SPIROADAMANTANE STABILIZING GROUP AND ARYLOXY MOIETY, WITH A PROTECTING GROUP THAT CAN BE REMOVED BY AN ENZYMATIC OR CHEMICAL TRIGGER; KIT FOR USE IN ASSAYS REQUIRING HIGH LIGHT INTENSITY, DETECTION SENSITIVITY | TROPIX, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5847161-A | 1, 2 chemiluminescent dioxetanes of improved performance | TROPIX, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5679803-A | 1,2 chemiluminescent dioxetanes of improved performance | TROPIX, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1997014692-A1 | 1,2 CHEMILUMINESCENT DIOXETANES OF IMPROVED PERFORMANCE | TROPIX, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0279698-A2 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CA12 498/4885CA1 272/4885CA2 1487/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | CA12 2745/4885CA1 3704/4885CA2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.